833 related articles for article (PubMed ID: 29293275)
1. Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters.
Millar BC; McCaughan J; Rendall JC; Downey DG; Moore JE
J Clin Pharm Ther; 2018 Feb; 43(1):92-100. PubMed ID: 29293275
[TBL] [Abstract][Full Text] [Related]
2. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study.
Millar BC; Rendall JC; Downey DG; Moore JE
J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786
[TBL] [Abstract][Full Text] [Related]
3. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.
Heltshe SL; Mayer-Hamblett N; Burns JL; Khan U; Baines A; Ramsey BW; Rowe SM;
Clin Infect Dis; 2015 Mar; 60(5):703-12. PubMed ID: 25425629
[TBL] [Abstract][Full Text] [Related]
4. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.
Rowe SM; Heltshe SL; Gonska T; Donaldson SH; Borowitz D; Gelfond D; Sagel SD; Khan U; Mayer-Hamblett N; Van Dalfsen JM; Joseloff E; Ramsey BW;
Am J Respir Crit Care Med; 2014 Jul; 190(2):175-84. PubMed ID: 24927234
[TBL] [Abstract][Full Text] [Related]
5. Combining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections.
Durfey SL; Pipavath S; Li A; Vo AT; Ratjen A; Carter S; Morgan SJ; Radey MC; Grogan B; Salipante SJ; Welsh MJ; Stoltz DA; Goss CH; McKone EF; Singh PK
mBio; 2021 Dec; 12(6):e0314821. PubMed ID: 34903059
[TBL] [Abstract][Full Text] [Related]
6. Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.
Harris JK; Wagner BD; Zemanick ET; Robertson CE; Stevens MJ; Heltshe SL; Rowe SM; Sagel SD
Ann Am Thorac Soc; 2020 Feb; 17(2):212-220. PubMed ID: 31604026
[No Abstract] [Full Text] [Related]
7. [Real-world effectiveness of ivacaftor in children with cystic fibrosis and the G551D mutation].
Gomez-Pastrana D; Nwokoro C; McLean M; Brown S; Christiansen N; Pao CS
An Pediatr (Engl Ed); 2019 Mar; 90(3):148-156. PubMed ID: 30093322
[TBL] [Abstract][Full Text] [Related]
8. An "Unlikely" Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI.
Schneider EK; Azad MA; Han ML; Tony Zhou Q; Wang J; Huang JX; Cooper MA; Doi Y; Baker MA; Bergen PJ; Muller MT; Li J; Velkov T
ACS Infect Dis; 2016 Jul; 2(7):478-88. PubMed ID: 27626100
[TBL] [Abstract][Full Text] [Related]
9. Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation.
Guimbellot JS; Baines A; Paynter A; Heltshe SL; VanDalfsen J; Jain M; Rowe SM; Sagel SD;
J Cyst Fibros; 2021 Mar; 20(2):213-219. PubMed ID: 33249004
[TBL] [Abstract][Full Text] [Related]
10. l-Methionine anti-biofilm activity against Pseudomonas aeruginosa is enhanced by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor.
Cho DY; Lim DJ; Mackey C; Weeks CG; Peña Garcia JA; Skinner D; Grayson JW; Hill HS; Alexander DK; Zhang S; Woodworth BA
Int Forum Allergy Rhinol; 2018 May; 8(5):577-583. PubMed ID: 29412515
[TBL] [Abstract][Full Text] [Related]
11. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function.
Zhang S; Shrestha CL; Kopp BT
Sci Rep; 2018 Nov; 8(1):17066. PubMed ID: 30459435
[TBL] [Abstract][Full Text] [Related]
12. Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation.
Sheikh SI; Long FR; McCoy KS; Johnson T; Ryan-Wenger NA; Hayes D
Clin Otolaryngol; 2015 Feb; 40(1):16-21. PubMed ID: 25145599
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol and ivacaftor are additive G551D CFTR-channel potentiators: therapeutic implications for cystic fibrosis sinus disease.
Cho DY; Zhang S; Lazrak A; Grayson JW; Peña Garcia JA; Skinner DF; Lim DJ; Mackey C; Banks C; Matalon S; Woodworth BA
Int Forum Allergy Rhinol; 2019 Jan; 9(1):100-105. PubMed ID: 30152192
[TBL] [Abstract][Full Text] [Related]
14. Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections.
Hisert KB; Heltshe SL; Pope C; Jorth P; Wu X; Edwards RM; Radey M; Accurso FJ; Wolter DJ; Cooke G; Adam RJ; Carter S; Grogan B; Launspach JL; Donnelly SC; Gallagher CG; Bruce JE; Stoltz DA; Welsh MJ; Hoffman LR; McKone EF; Singh PK
Am J Respir Crit Care Med; 2017 Jun; 195(12):1617-1628. PubMed ID: 28222269
[TBL] [Abstract][Full Text] [Related]
15. Mutual Effects of Single and Combined CFTR Modulators and Bacterial Infection in Cystic Fibrosis.
Cigana C; Giannella R; Colavolpe A; Alcalá-Franco B; Mancini G; Colombi F; Bigogno C; Bastrup U; Bertoni G; Bragonzi A
Microbiol Spectr; 2023 Feb; 11(1):e0408322. PubMed ID: 36625583
[TBL] [Abstract][Full Text] [Related]
16. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
Davies J; Sheridan H; Bell N; Cunningham S; Davis SD; Elborn JS; Milla CE; Starner TD; Weiner DJ; Lee PS; Ratjen F
Lancet Respir Med; 2013 Oct; 1(8):630-638. PubMed ID: 24461666
[TBL] [Abstract][Full Text] [Related]
17. Anti-Infectives Restore ORKAMBI
Laselva O; Stone TA; Bear CE; Deber CM
Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32092967
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal Trends in Real-World Outcomes after Initiation of Ivacaftor. A Cohort Study from the Cystic Fibrosis Registry of Ireland.
Kirwan L; Fletcher G; Harrington M; Jeleniewska P; Zhou S; Casserly B; Gallagher CG; Greally P; Gunaratnam C; Herzig M; Linnane B; McElvaney NG; McKone EF; McNally P; Mullane D; Ní Chróinín M; O'Mahony M; Plant BJ; Jackson AD
Ann Am Thorac Soc; 2019 Feb; 16(2):209-216. PubMed ID: 30427731
[TBL] [Abstract][Full Text] [Related]
19. The success of the different eradication therapy regimens for Pseudomonas aeruginosa in cystic fibrosis.
Emiralioglu N; Yalcin E; Meral A; Sener B; Dogru D; Ozcelik U; Kiper N
J Clin Pharm Ther; 2016 Aug; 41(4):419-23. PubMed ID: 27311742
[TBL] [Abstract][Full Text] [Related]
20. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.
Ren CL; Morgan RL; Oermann C; Resnick HE; Brady C; Campbell A; DeNagel R; Guill M; Hoag J; Lipton A; Newton T; Peters S; Willey-Courand DB; Naureckas ET
Ann Am Thorac Soc; 2018 Mar; 15(3):271-280. PubMed ID: 29342367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]